

## Clinical Policy: Luspatercept-aamt (Reblozyl)

Reference Number: ERX.SPA.361

Effective Date: 03.01.20

Last Review Date: 02.22

Line of Business: Commercial, Medicaid

[Revision Log](#)

See **Important Reminder** at the end of this policy for important regulatory and legal information.

### Description

Luspatercept-aamt (Reblozyl<sup>®</sup>) is an erythroid maturation agent

### FDA Approved Indication(s)

Reblozyl is indicated for the treatment of anemia in adult patients with

- Beta thalassemia who require regular red blood cell (RBC) transfusions
- Very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) failing an erythropoiesis stimulating agent and requiring 2 or more RBC units over 8 weeks

Limitation(s) of use: Not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

*Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary.*

It is the policy of health plans affiliated with Envolve Pharmacy Solutions<sup>™</sup> that Reblozyl is **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Transfusion Dependent Beta Thalassemia (must meet all):

1. Diagnosis of transfusion dependent thalassemia (TDT) with one of the following genotypes (a or b):
  - a. Beta thalassemia;
  - b. Hemoglobin E/beta thalassemia;
2. Prescribed by or in consultation with a hematologist;
3. Age  $\geq$  18 years;
4. Total volume of transfusions exceeds 6 RBC units (*see Appendix D*) within the last 6 months;
5. No transfusion-free period  $\geq$  35 days within the last 6 months;
6. Documentation of baseline transfusion burden within the last 6 months;
7. Dose does not exceed 1 mg/kg every 3 weeks.

**Approval duration: 2 months (2 doses)**

##### B. Myelodysplastic Syndromes (must meet all):

1. Diagnosis of MDS-RS or MDS/MPN-RS-T that meets one of the following classifications (a, b, or c) (*see Appendix E*):
  - a. Very low, low, or intermediate risk as classified by IPSS-R;
  - b. Low/intermediate-1 risk as classified by IPSS;
  - c. Very low, low, or intermediate risk as classified by WPSS;
2. Prescribed by or in consultation with a hematologist or oncologist;
3. Age  $\geq$  18 years;
4. Member requires  $\geq$  2 RBC units per 8 weeks documented for at least the last 16 weeks;

5. Failure of an 8 week trial of an erythropoiesis-stimulating agent (ESA) used in combination with a granulocyte colony stimulating factor (G-CSF) (see *Appendix B*), unless one of the following applies (a or b):
  - a. Clinically significant adverse effects are experienced or all are contraindicated;
  - b. Documentation of current serum erythropoietin > 500 mU/mL;
6. Member has one of the following (a or b):
  - a. Ring sideroblast  $\geq$  15% of erythroid precursors in bone marrow;
  - b. Ring sideroblast  $\geq$  5% if SF3B1 mutation is present;
7. Member does not have del(5q) cytogenetic abnormality;
8. Request meets one of the following (a or b):\*
  - a. Dose does not exceed 1 mg/kg every 3 weeks;
  - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

*\*Prescribed regimen must be FDA-approved or recommended by NCCN*

**Approval duration: 2 months (2 doses)**

**C. Other diagnoses/indications**

1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

**II. Continued Therapy**

**A. Transfusion Dependent Beta Thalassemia (must meet all):**

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met all initial approval criteria;
2. Member meets one of the following (a or b):
  - a. Member is responding positively to therapy as evidenced by at least a 33% reduction in transfusion burden from baseline;
  - b. Request is for a dose increase;
3. If request is for a dose increase, new dose does not exceed (a or b):
  - a. 1 mg/kg every 3 weeks;
  - b. 1.25 mg/kg every 3 weeks, and documentation supports inadequate response to 1 mg/kg dosing.

**Approval duration: 6 months**

**B. Myelodysplastic Syndromes (must meet all):**

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions, or documentation supports that member is currently receiving Reblozyl for a covered indication and has received this medication for at least 30 days;
2. Member meets one of the following (a or b):
  - a. Member is responding positively to therapy as evidenced by a decreased transfusion burden;
  - b. Request is for a dose increase;
3. If request is for a dose increase, request meets one of the following (a, b, c, or d):\*
  - a. New dose does not exceed 1 mg/kg every 3 weeks;
  - b. New dose does not exceed 1.33 mg/kg every 3 weeks, and documentation supports lack of transfusion independence after 2 consecutive doses at 1 mg/kg dosing;
  - c. New dose does not exceed 1.75 mg/kg every 3 weeks, and documentation supports lack of transfusion independence after 2 consecutive doses at 1.33 mg/kg dosing;
  - d. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

*\*Prescribed regimen must be FDA-approved or recommended by NCCN*

**Approval duration: 6 months (2 months [2 doses] if request is for a dose increase)**

**C. Other diagnoses/indications (must meet 1 or 2):**

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy.

- Approval duration: Duration of request or 6 months (whichever is less);** or
2. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – ERX.PA.01 or evidence of coverage documents.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

FDA: Food and Drug Administration

FDA: Food and Drug Administration

G-CSF: granulocyte colony stimulating factor

Hb: hemoglobin

IPSS: International Prognostic Scoring System

IPSS-R: International Prognostic Scoring System - Revised

MDS: myelodysplastic syndromes

MDS-RS: myelodysplastic syndromes with ring sideroblasts

MDS/MPN-RS-T: myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

TDT: transfusion dependent thalassemia

WPSS: WHO Classification-based Scoring System

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria.*

*The drugs listed here may not be a formulary agent and may require prior authorization.*

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Procrit <sup>®</sup> , Epogen <sup>®</sup> , Retacrit <sup>®</sup> (epoetin alfa)*	MDS: 40,000 to 60,000 SC units 1 to 2 times per week every week	Target hemoglobin up to 12 g/dL
Aranesp <sup>®</sup> (darbepoetin alfa)*	MDS: 150 to 300 mcg SC every other week	Target hemoglobin up to 12 g/dL
Neupogen <sup>®</sup> , Nivestym <sup>™</sup> , Granix <sup>®</sup> , Zarxio <sup>®</sup> (filgrastim)	MDS: 1 to 2 mcg/kg SC 1 to 2 times per week	Varies

*Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.*

*\*Off-label*

*Appendix C: Contraindications/Boxed Warnings*

None reported

*Appendix D: General Information*

- Conversion of RBC units from mL: 1 RBC unit in this criteria refers to a quantity of packed RBCs approximately 200-350 mL.
  - Sites who use transfusion bags within this range, or ≥ 350 mL, the conversion in units should be done by dividing the volume transfused to the patient by 350 mL,
  - Sites who use transfusion bags < 200 mL, the conversion in units should be done by dividing the volume transfused to the patient by 200 mL.
- MDS and serum erythropoietin level
  - According to NCCN, for the treatment of symptomatic anemia in MDS with ring sideroblasts ≥ 15% (or ring sideroblasts ≥ 5% with an SF3B1 mutation), a trial of either recombinant human erythropoietin or darbepoetin in combination with a G-CSF is recommended when serum erythropoietin level is ≤ 500 mU/mL. If serum erythropoietin level is > 500 mU/mL for this indication, Reblozyl is recommended.

- MDS and combination treatment with ESA + G-CSF
  - This is the recommended combination per NCCN for the treatment of symptomatic anemia in MDS with ring sideroblasts  $\geq 15\%$  (or ring sideroblasts  $\geq 5\%$  with an SF3B1 mutation). Evidence suggests that G-CSF has synergistic erythropoietic activity when used in combination with an ESA and markedly enhances the erythroid response rates due to enhanced survival of red cell precursors. This is particularly evident for patients with greater than or equal to 15% ring sideroblasts in the marrow and serum erythropoetin level  $\leq 500$  mU/mL.
- MDS/MPN-RS-T indication
  - During regulatory review of the MEDALIST data by the FDA, a post-hoc re-classification of patients using the WHO 2016 criteria was conducted to assess the efficacy and safety of Reblozyl in patients with MDS/MPN-RS-T. Among the 229 patients enrolled in MEDALIST, 23 patients were found to have a diagnosis of MDS/MPN-RS-T following this re-classification. In these patients with MDS/MPN-RS-T, a greater proportion of patients treated with Reblozyl (64.3%; n = 9/14) achieved the primary endpoint of transfusion independence for at least 8 weeks during weeks 1-24 compared to placebo (22.2%; n = 2/9).

*Appendix E: MDS Risk Classification*

- International Prognostic Scoring System - Revised (IPSS-R) classification:

Risk Category	Risk Score
Very low	$\leq 1.5$
Low	$< 1.5 - 3$
Intermediate	$< 3 - 4.5$
High	$< 4.5 - 6$
Very high	$> 6$

- International Prognostic Scoring System (IPSS) classification:

Risk Category	Risk Score
Low	0
Intermediate-1	0.5 – 1
Intermediate-2	1.5 – 2
High	2.5 – 3.5

- WHO Classification-based Prognostic Scoring System (WPSS) classification:

Risk Category	Risk Score
Very low	0
Low	1
Intermediate	2
High	3 – 4
Very high	5 – 6

**V. Dosage and Administration**

Indication	Dosing Regimen	Maximum Dose
Transfusion-dependent beta thalassemia	1 mg/kg SC once every 3 weeks  If a patient does not achieve a reduction in RBC transfusion burden after at least 2 consecutive doses (6 weeks) at the 1 mg/kg starting dose, increase to max dose of 1.25 mg/kg	1.25 mg/kg
MDS	<u>Initial:</u> 1 mg/kg SC once every 3 weeks  <u>Dose increases for insufficient response after initiation of treatment:</u> If a patient is not RBC transfusion-free after at least 2 consecutive doses (6 weeks) at the 1 mg/kg starting dose, increase the dose to 1.33 mg/kg SC every 3 weeks.	1.75 mg/kg

Indication	Dosing Regimen	Maximum Dose
	<p>If a patient is not RBC transfusion-free after at least 2 consecutive doses (6 weeks) at the 1.33 mg /kg dose level, increase the dose to a maximum of 1.75 mg/kg SC every 3 weeks.</p> <p>Discontinue if a patient does not experience a decrease in transfusion burden after 9 weeks of treatment (administration of 3 doses) at the maximum dose level or if unacceptable toxicity occurs at any time</p>	

**VI. Product Availability**

Single dose vials for injection: 25 mg, 75 mg

**VII. References**

1. Reblozyl Prescribing Information. Cambridge, MA: Acceleron Pharma, Inc. October 2021. Available at: [www.reblozyl.com](http://www.reblozyl.com). Accessed November 14, 2021.
2. Cappellini MD, Vipralasit V, Taher A, et al. The BELIEVE Trial: Results of a phase 3, randomized, double-blind, placebo-controlled study of luspatercept in adult beta-thalassemia patients who require regular red blood cell (RBC) transfusions [Oral]. Oral presented at: 60<sup>th</sup> American Society of Hematology Annual Meeting and Exposition (ASH); December 1-4, 2018; San Diego, CA.
3. Cappellini MD, Farmakis D, Porter J, et al. 2021 Guidelines for the management of transfusion dependent thalassemia (TDT) 4<sup>th</sup> Edition. Thalassemia International Federation (2021). Available at: <https://thalassaemia.org.cy/wp-content/uploads/2021/06/GUIDELINE-4th-DIGITAL-BY-PAGE.pdf>.
4. Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. *N Engl J Med*. 2020;382:140-151.
5. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: [http://www.nccn.org/professionals/drug\\_compendium](http://www.nccn.org/professionals/drug_compendium). Accessed November 14, 2021.
6. National Comprehensive Cancer Network. Myelodysplastic Syndromes Version 2.2022. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/mds.pdf](https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf). Accessed November 14, 2021.
7. Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T) – “2019 Update on Diagnosis, Risk-stratification, and Management.” *Am J Hematol*. 2019;94(4): 475–488.
8. Reblozyl Data on File. Use of Reblozyl (luspatercept-aamt) in patients with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Bristol Meyers Squibb. 2020 May.

**ICD-10-CM Diagnosis Codes that Support Coverage Criteria**

The following is a list of diagnosis codes that support coverage for the applicable covered procedure code(s).

ICD-10-CM Code	Description
D56.1*	Beta thalassemia

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created	12.10.19	02.20
Criteria added for new FDA indication: MDS; for transfusion dependent beta thalassemia, added “within the last 6 months” for RBC and transfusion-free period requirements; added initial criteria requiring documentation of baseline transfusion burden within the last 6 months; references reviewed and updated.	05.26.20	08.20
1Q 2021 annual review: no significant changes; references reviewed and updated.	10.27.20	02.21

Reviews, Revisions, and Approvals	Date	P&T Approval Date
1Q 2022 annual review: no significant changes; references reviewed and updated.	11.14.21	02.22

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.

This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

©2020 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.